Cerebral Amyloid Angiopathy (CAA)

Migration, Crosslink

📖

Cerebral Amyloid Angiopathy (CAA)

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-cerebral-amyloid-angiopath

📖 Wiki Page

disease2530 wordssynced 2026-04-02

Cerebral Amyloid Angiopathy: Mechanism and Neurodegeneration

Overview

Cerebral Amyloid Angiopathy: Mechanism and Neurodegeneration is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Cerebral Amyloid Angiopathy (CAA) is a cerebrovascular disease characterized by the deposition of [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides in the walls of small to medium-sized blood vessels in the brain[@charidimou2015]. This condition is a major contributor to cognitive decline and hemorrhagic stroke in elderly individuals, and it's closely linked to [Alzheimer's disease](/diseases/alzheimers-disease) pathophysiology.

Pathophysiology

Amyloid Deposition in Cerebral Vessels

CAA involves the accumulation of [amyloid-beta](/proteins/amyloid-beta) peptides, predominantly Aβ40, in the media and adventitia of leptomeningeal and cortical arterioles, capillaries, and venules[@keable2016]. Unlike the diffuse plaques characteristic of [Alzheimer's disease](/diseases/alzheimers-disease), CAA represents a vascular form of amyloid accumulation.

...

Cerebral Amyloid Angiopathy: Mechanism and Neurodegeneration

Overview

Cerebral Amyloid Angiopathy: Mechanism and Neurodegeneration is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Cerebral Amyloid Angiopathy (CAA) is a cerebrovascular disease characterized by the deposition of [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides in the walls of small to medium-sized blood vessels in the brain[@charidimou2015]. This condition is a major contributor to cognitive decline and hemorrhagic stroke in elderly individuals, and it's closely linked to [Alzheimer's disease](/diseases/alzheimers-disease) pathophysiology.

Pathophysiology

Amyloid Deposition in Cerebral Vessels

CAA involves the accumulation of [amyloid-beta](/proteins/amyloid-beta) peptides, predominantly Aβ40, in the media and adventitia of leptomeningeal and cortical arterioles, capillaries, and venules[@keable2016]. Unlike the diffuse plaques characteristic of [Alzheimer's disease](/diseases/alzheimers-disease), CAA represents a vascular form of amyloid accumulation.

Key Features:

Aβ40 predominance: While Aβ42 is more aggregation-prone and found in parenchymal plaques, Aβ40 is the predominant isoform in CAA due to its higher affinity for cerebral blood vessel walls[@herzig2007]
APOE4 association: The [APOE ε4 allele](/mechanisms/apoe-lipid-pathway) strongly increases CAA risk and severity
Vascular localization: Amyloid deposits are found primarily in the:
Leptomeningeal arterioles
Cortical penetrating arterioles
Capillaries
Small veins (less commonly)

Vascular Changes

The amyloid deposition triggers significant structural and functional changes in cerebral vessels:

Vascular wall thickening: Amyloid accumulation in the media replaces smooth muscle cells, leading to vessel wall thickening and rigidity[@vinters1987]

Loss of smooth muscle cells: Progressive loss of smooth muscle cells compromises vessel structural integrity

Vessel rupture risk: Weakened vessels become prone to hemorrhagic complications

[Blood-brain barrier](/entities/blood-brain-barrier) dysfunction: CAA compromises the blood-brain barrier, facilitating further Aβ deposition and neuroinflammation[@zlokovic2011]

Vascular Smooth Muscle Cell Dysfunction

Vascular smooth muscle cells (VSMCs) are primary targets of Aβ deposition in CAA. These cells play critical roles in maintaining cerebrovascular tone, vessel integrity, and blood flow regulation. Aβ-induced VSMC dysfunction represents a central pathogenic mechanism[@van2020].

Morphological Changes:

Cytoplasmic vacuolization: Early indicator of Aβ-induced injury
Nuclear pyknosis: Evidence of apoptotic cell death
Complete cell loss: Advanced CAA shows near-complete VSMC replacement by amyloid
Media thinning: Vessel wall thickness increases while smooth muscle content decreases[@weller2015]

Functional Impairment:

Contractile dysfunction: Loss of contractile phenotype, transitioning to synthetic state
Impaired autoregulation: Reduced ability to maintain constant cerebral blood flow
Dysregulated matrix maintenance: Altered production of extracellular matrix proteins
Endothelial decoupling: Loss of endothelial-VSMC signaling coordination[@blair2021]

Mechanisms of VSMC Injury:

Direct Aβ toxicity: Aβ40 binding to VSMC receptors triggers intracellular calcium dysregulation

[Reactive oxygen species](/entities/reactive-oxygen-species): Increased oxidative stress damages cellular components

Inflammatory activation: Pro-inflammatory cytokine release amplifies injury

[Autophagy](/entities/autophagy) impairment: Defective autophagic clearance leads to cellular stress

Mitochondrial dysfunction: Energy production deficits accelerate cell death[@mori2022]

The loss of VSMCs creates a feedback loop: damaged vessels allow increased Aβ infiltration, which causes further VSMC loss. This progressive deterioration underlies the clinical progression from asymptomatic amyloid deposition to symptomatic vasculopathy.

Pericyte Injury in CAA

Cerebral [pericytes](/cell-types/pericytes) are perivascular cells that ensheath capillary endothelial cells and play essential roles in blood-brain barrier maintenance, capillary blood flow regulation, and vascular stability. Pericyte injury is increasingly recognized as a critical component of CAA pathogenesis[@sagare2013].

Pericyte-Aβ Interactions:

Direct pericyte binding: Aβ peptides bind to pericyte surface receptors including CD36 and [RAGE](/genes/rage)
Cellular uptake: Pericytes can internalize Aβ, but clearance capacity is limited
Toxic accumulation: Internalized Aβ accumulates in pericyte cytoplasm, causing dysfunction

Pathological Consequences:

Blood-brain barrier breakdown: Pericyte loss leads to increased BBB permeability[@bell2010]
Capillary instability: Weakened pericyte-endothelial connections cause leakage
Impaired Aβ clearance: Reduced pericyte-mediated vascular clearance of Aβ
Neuroinflammation: Activated pericytes release pro-inflammatory mediators[@wilhelm2019]

Pericyte Loss in CAA:

Quantitative studies show 30-50% reduction in pericyte coverage in CAA-affected vessels
Pericyte loss correlates with severity of CAA and cognitive impairment
APOE4 carriers show accelerated pericyte degeneration

Therapeutic Implications:

Pericyte-protective strategies may preserve BBB function in CAA
Enhancing pericyte Aβ clearance could reduce vascular amyloid burden
VEGF and PDGFR-β signaling represent potential intervention points[@nakamura2023]

Hemorrhagic Complications

Hemorrhagic complications represent the most feared clinical sequelae of CAA. The structural and functional changes in cerebral vessels create susceptibility to life-threatening bleeding events[@van2020a].

Pathogenesis of Hemorrhage

Vessel Wall Weakness:

Amyloid deposition replaces structural components
Smooth muscle cell loss eliminates contractile capacity
Extracellular matrix degradation weakens connective tissue
Hypertension exacerbates these vulnerabilities

Hemorrhage Types:

| Type | Frequency | Clinical Significance |
|------|-----------|----------------------|
| Lobar intracerebral hemorrhage | Most common | High mortality, recurrence risk |
| Cerebral microbleeds | Very common | Imaging biomarker, hemorrhage risk |
| Subarachnoid hemorrhage | Less common | Acute presentation |
| Superficial siderosis | Chronic | Progressive neurological decline |

Lobar Intracerebral Hemorrhage:

Accounts for 70-80% of CAA-related hemorrhages
Location: lobar ([cortex](/brain-regions/cortex)/subcortical), not deep (basal ganglia/thalamus)
Often recurrent: 10-30% recurrence rate within 2 years
Mortality: 30-day mortality rates of 30-50%[@meretoja2020]

Cerebral Microbleeds (CMBs):

Small hemorrhages detected on MRI T2* gradient echo sequences
Distribution pattern: lobar (cortical/subcortical) in CAA vs. deep in hypertensive vasculopathy
Number correlates with CAA severity and future hemorrhage risk
Prevalence: 20-30% in community-dwelling elderly, up to 60% in CAA patients[@greenberg2020]

Cortical Superficial Siderosis (CSS):

Chronic blood product deposition in cortical sulci
Presents with progressive neurological decline
Associated with recurrent cortical hemorrhages
Important diagnostic feature for CAA[@charidimou2019]

Risk Factors for Hemorrhage

Amyloid burden: Greater vascular amyloid correlates with higher hemorrhage risk

[APOE](/genes/apoe) genotype: APOE ε4 and ε2 alleles increase hemorrhage risk[@biffi2012]

Anticoagulation: Warfarin and DOACs significantly elevate hemorrhage risk

Hypertension: Contributes to vessel rupture, particularly in combination with CAA

Prior hemorrhage: History of lobar ICH is strongest predictor of recurrence

Management Considerations

Acute hemorrhage: Standard stroke/neurocritical care protocols
Anticoagulation reversal: For patients on anticoagulation with ICH
Blood pressure control: Moderate targets to reduce rebleeding risk
Antiplatelet therapy: Must be carefully weighed against hemorrhage risk
Surgical intervention: evacuation may be beneficial for large lobar hemorrhages

Neuroinflammation is a hallmark of CAA pathophysiology, involving both vascular and parenchymal inflammatory responses that contribute to disease progression and clinical manifestations[@michaud2023].

Vascular Inflammation:

Perivascular [microglia](/cell-types/microglia) activation: Cluster around amyloid-laden vessels
Astrocytic reactivity: Hypertrophic [astrocytes](/cell-types/astrocytes) surrounding affected vessels
Lymphocytic infiltration: T-cells and occasionally B-cells in vessel walls
Complement activation: C1q and MAC deposition on vascular amyloid[@ishida2021]

Inflammatory Mediators:

| Mediator | Source | Effect in CAA |
|----------|--------|---------------|
| IL-1β | Microglia, astrocytes | Pro-inflammatory, promotes Aβ production |
| IL-6 | Multiple cell types | Acute phase response, modulates immunity |
| TNF-α | Microglia, astrocytes | Cytotoxic, disrupts BBB |
| CCL2 | Pericytes, endothelial | Monocyte recruitment |
| CX3CL1 | [Neurons](/entities/neurons), endothelial | Microglial activation state |

Cerebral Amyloid Angiopathy-Related Inflammation (CAA-RI):
A distinct clinicopathological variant characterized by:

Vasogenic edema: T2/FLAIR hyperintensities
Cortical swelling: Mass effect on MRI
Acute presentations: Headache, seizures, focal deficits
Steroid responsiveness: Improvement with immunosuppressive therapy[@calviere2020]

Mechanisms of Inflammation:

Aβ as pro-inflammatory stimulus: Aβ activates pattern recognition receptors

[NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome): Microglial activation triggers IL-1β release

Complement cascade: Classical pathway activation by Aβ-antibody complexes

Reactive oxygen species: Oxidative stress amplifies inflammatory responses

Blood-brain barrier breach: Peripheral immune cell infiltration[@heneka2015]

Neurovascular Unit Dysfunction:

Bidirectional communication between endothelial cells, pericytes, smooth muscle cells, and glial cells breaks down
Impaired neurovascular coupling reduces cerebral blood flow regulation
Cumulative inflammation accelerates neurodegenerative processes

Inflammation as Therapeutic Target:

Anti-inflammatory approaches: NSAIDs show mixed results in trials
Microglial modulation: Colony-stimulating factor 1 receptor (CSF1R) antagonists
Complement inhibition: C1q and C3 blockers in development
Immunomodulation: Targeting specific cytokine pathways[@baltan2023]

Relationship to Alzheimer's Disease

CAA and [Alzheimer's disease](/diseases/alzheimers-disease) share significant pathological overlap:

Shared amyloid pathology: Both conditions involve [amyloid-beta](/proteins/amyloid-beta) accumulation, though in different compartments
Prevalence correlation: Approximately 80-90% of AD patients have some degree of CAA[@jellinger2020]
Independent cognitive impact: CAA contributes to cognitive decline independently of parenchymal plaques and [tau](/mechanisms/tau-pathology) neurofibrillary tangles
Vascular pathway: CAA represents a "vascular route" of Aβ clearance dysfunction
Synergistic pathology: When CAA coexists with AD, cognitive decline is accelerated

Aβ Clearance Pathways

CAA is thought to result from impaired Aβ clearance from the brain:

| Pathway | Normal Function | CAA Implication |
|---------|-----------------|-----------------|
| Perivascular drainage | Aβ clearance along arterial walls | Impaired in CAA |
| [Glymphatic system](/entities/glymphatic-system) | Aβ clearance during sleep | Sleep disruption in CAA |
| Cellular uptake | Microglial and astrocytic clearance | Reduced in aging |
| Proteolytic degradation | [Neprilysin](/entities/neprilysin), [IDE](/proteins/ide-protein)-mediated clearance | Reduced enzyme activity |

Clinical Manifestations

Cognitive Symptoms

Progressive cognitive decline: Often indistinguishable from AD initially
Executive function impairment: Particularly affected due to frontal-subcortical circuit involvement
Psychomotor slowing: Reduced processing speed
Behavioral changes: Apathy, disinhibition

Neurological Features

Transient focal neurological episodes: "Amyloid spells" - recurrent, stereotyped episodes
Seizures: More common than in AD alone
Gait disturbance: Due to white matter changes and frontal dysfunction
Parkinsonism: Can present with parkinsonian features

Diagnosis

Neuroimaging Markers

MRI findings:

Cortical microbleeds (gradient-echo T2*)
White matter hyperintensities
Cortical superficial siderosis
Recent small subcortical hemorrhages

PET imaging:

Pittsburgh Compound B (PiB) binding shows cerebrovascular amyloid

CSF analysis:

Reduced Aβ40 levels (reflecting cerebral amyloid burden)
Normal total [tau](/proteins/tau) and phosphorylated [tau](/proteins/tau)

Diagnostic Criteria (Boston Criteria 2.0)

| Certainty Level | Criteria |
|-----------------|----------|
| Definite CAA | Pathological confirmation |
| Probable CAA with supporting evidence | Clinical data + MRI/CSF biomarkers |
| Probable CAA | Clinical data alone |
| Possible CAA | Atypical presentation |

Treatment Approaches

Acute Management

Hemorrhage management: Standard stroke protocols
Seizure control: Antiepileptic medications
Blood pressure optimization: Caution with aggressive lowering

Disease-Modifying Strategies

Anti-amyloid therapies ([anti-amyloid therapeutics](/mechanisms/anti-amyloid-therapeutics)):

Immunotherapies ([Aduhelm](/therapeutics/aducanumab), [Lecanemab](/therapeutics/lecanemab)) may reduce CAA burden
Passive immunization against Aβ40/Aβ42

Vascular protective strategies:

Antihypertensive medications
Statins for vascular health
Antiplatelet agents (controversial due to bleeding risk)

Lifestyle interventions:

Sleep optimization (glymphatic clearance)
Physical exercise
Cognitive stimulation

Clinical Trials

Active and Recent Trials

Several clinical trials are investigating CAA-targeted therapies:

Anti-amyloid immunotherapies: Trials of [lecanemab](/therapeutics/lecanemab) and [donanemab](/therapeutics/donanemab) include CAA as a secondary outcome measure

Vascular protective agents: Studies of antithrombotics and blood pressure management in CAA patients

Diagnostic biomarker trials: MRI and PET-based studies to improve CAA detection and monitoring

[APOE](/proteins/apoe-protein)-targeted approaches: Gene therapy and small molecule trials for APOE4 carriers with CAA

For current clinical trial listings, see [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease).

Research Directions

Biomarker Development

Vascular amyloid PET ligands: Next-generation imaging tracers
Blood-based biomarkers: Plasma Aβ40/Aβ42 ratios
MicroRNA signatures: Circulating vascular disease markers

Therapeutic Targets

Vascular Aβ clearance enhancement
Perivascular drainage improvement
Blood-brain barrier repair
Anti-inflammatory approaches

APOE Association

The [APOE gene](/apoe-gene) is a major genetic determinant of CAA:

APOE4 and CAA Risk

Dose-dependent effect: Carrying one [APOE](/proteins/apoe-protein) ε4 allele increases CAA risk 2-3 fold; homozygotes have even higher risk[@togo2002]
Earlier onset: APOE4 carriers develop CAA at younger ages
Increased severity: More severe vascular amyloid deposition
Hemorrhage risk: Higher risk of lobar intracerebral hemorrhage

Mechanisms

Enhanced Aβ binding: APOE4 has higher affinity for Aβ40

Impaired vascular clearance: Reduced perivascular drainage of Aβ

Blood-brain barrier effects: APOE4 exacerbates BBB dysfunction

Neuroinflammation: Amplified inflammatory response to vascular amyloid

Clinical Implications

[APOE](/genes/apoe) genotyping informs CAA diagnosis and prognosis
Anti-amyloid immunotherapies show variable efficacy by APOE genotype
APOE4 carriers require careful monitoring during anticoagulation therapy

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Visual Summary

Mermaid diagram (expand to render)

Key Pathway Steps:

Abeta40 production via [APP](/entities/app-protein) processing

Deposition in cerebral vessel walls

Vessel wall thickening and smooth muscle loss

BBB dysfunction leading to hemorrhage and inflammation

Resulting cognitive decline

References

[Charidimou A et al., Cerebral amyloid angiopathy: emerging concepts. J Neurol Neurosurg Psychiatry. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25677456/)

[Keable A et al., Deposition of amyloid-beta in the walls of human leptomeningeal vessels in the context of cerebral amyloid angiopathy. Acta Neuropathol. 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/26472561/)

[Herzig MC et al., Aβ40 is more potent than Aβ42 at causing cerebrovascular amyloid accumulation. Acta Neuropathol. 2007 (2007)](https://pubmed.ncbi.nlm.nih.gov/17431613/)

[Unknown, Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke. 1987 (1987)](https://pubmed.ncbi.nlm.nih.gov/3554512/)

[Unknown, Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21706034/)

[Van Drossen L et al., Vascular smooth muscle cells in cerebral amyloid angiopathy. J Cereb Blood Flow Metab. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32840326/)

[Weller RO et al., Perivascular drainage of amyloid-beta from the brain: implications for Alzheimer therapy. Nat Rev Neurol. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/26080866/)

[Blair LJ et al., Strategies to improve cerebrovascular smooth muscle function in aging and Alzheimer's. Aging Cell. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34096511/)

[Mori T et al., Arterial smooth muscle cell pathology in cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35832095/)

[Sagare AP et al., Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/24309554/)

[Bell RD et al., Pericytes control key neurovascular functions and neuronal activity. Nature. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/21131956/)

[Wilhelm I et al., Pericyte injury in cerebral amyloid angiopathy. Acta Neuropathol Commun. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31126372/)

[Nakamura M et al., Pericyte-targeted therapies for cerebrovascular disease. Transl Stroke Res. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37335181/)

[van den Brink HJ et al., Cerebral amyloid angiopathy and hemorrhage. Stroke. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32805005/)

[Meretoja A et al., Lobar intracerebral hemorrhage: clinical features and outcomes. Neurology. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32493847/)

[Greenberg SM et al., Cerebral microbleeds: a guide to detection and clinical implications. Lancet Neurol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32155384/)

[Charidimou A et al., Cortical superficial siderosis: consensus on diagnostic criteria. Neurology. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31092652/)

[Biffi A et al., Genetic variants influencing recurrent hemorrhage in patients with CAA. Neurology. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22592366/)

[Michaud JP et al., Neuroinflammation in cerebral amyloid angiopathy. J Neuroinflammation. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38162891/)

[Ishida K et al., Complement activation in CAA-related inflammation. Acta Neuropathol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34050355/)

[Calviere L et al., Cerebral amyloid angiopathy-related inflammation: clinical features and response to treatment. Neurology. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32709767/)

[Heneka MT et al., Neuroinflammation in Alzheimer's disease: NLRP3 inflammasome and pathological implications. Nat Rev Neurol. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25645400/)

Baltan S et al., Targeting inflammation in cerebral amyloid angiopathy: emerging therapeutic strategies. Neuroscientist. 2023 (2023)

[Unknown, Jellinger KA. Prevalence and impact of cerebrovascular pathology in Alzheimer's disease. J Neural Transm. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32052476/)

[Togo T et al., Apolipoprotein E epsilon 4 association with cerebral amyloid angiopathy. Acta Neuropathol. 2002 (2002)](https://pubmed.ncbi.nlm.nih.gov/11885741/)

📖 View canonical wiki page →

Related Entities

diseases-cerebral-amyloid-angiopathy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-cerebral-amyloid-angiopathy
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-840119afd22e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-cerebral-amyloid-angiopathy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

34

Outgoing

51

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cerebral Amyloid Angiopathy (CAA)

Cerebral Amyloid Angiopathy: Mechanism and Neurodegeneration

Overview

Pathophysiology

Amyloid Deposition in Cerebral Vessels

Cerebral Amyloid Angiopathy: Mechanism and Neurodegeneration

Overview

Pathophysiology

Amyloid Deposition in Cerebral Vessels

Vascular Changes

Vascular Smooth Muscle Cell Dysfunction

Pericyte Injury in CAA

Hemorrhagic Complications

Pathogenesis of Hemorrhage

Risk Factors for Hemorrhage

Management Considerations

CAA-Related Inflammation

Relationship to Alzheimer's Disease

Aβ Clearance Pathways

Clinical Manifestations

Cognitive Symptoms

Neurological Features

Diagnosis

Neuroimaging Markers

Diagnostic Criteria (Boston Criteria 2.0)

Treatment Approaches

Acute Management

Disease-Modifying Strategies

Clinical Trials

Active and Recent Trials

Research Directions

Biomarker Development

Therapeutic Targets

APOE Association

APOE4 and CAA Risk

Mechanisms

Clinical Implications

See Also

External Links

Visual Summary

References

💬 Discussion